Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug/Diagnostic Partnerships Fueled By Promise Of Reduced Trial Costs

This article was originally published in The Gray Sheet

Executive Summary

Diagnostic manufacturers should be careful to keep their alliances with drug companies open enough to accommodate pharmacogenomic advances, panelists agreed at Thomas Weisel Partners' Healthcare Tailwinds 2002 meeting in Boston April 29
Advertisement

Related Content

Pharmacogenomic Progress Hinges On Strong Pharma Backing – Consultant
Pharmacogenomic Progress Hinges On Strong Pharma Backing – Consultant
Test Would Assess Risk Of Cardiovascular Disease Using Enzyme’s Presence
Test Would Assess Risk Of Cardiovascular Disease Using Enzyme’s Presence
Ventana Developing Companion Diagnostic For Novartis’ Gleevec Cancer Drug
Ventana Developing Companion Diagnostic For Novartis’ Gleevec Cancer Drug
Abbott/Vysis PathVysion HER-2 Test Labeling Cleared To Carry Herceptin
Abbott/Vysis PathVysion HER-2 Test Labeling Cleared To Carry Herceptin
NCI-FDA Panel Will Publish Draft Guidelines On Cancer Assay Development
Advertisement
UsernamePublicRestriction

Register

MT016535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel